RxDoctor Payments Data

Mahmood Rana, MD

Internal Medicine · South Yarmouth, MANPI 1285843169

Payments from drug & device makers

$307in general payments, 2019–2025

Across 15 payments — averaging $20.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Novo Nordisk$111
  • AstraZeneca$59
  • Abbott$35
  • Lilly USA, LLC$33
  • Pfizer$20
  • GSK$18
  • plus $31 from 2 others

What the payments were for

  • Food & beverage$307100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Novo Nordisk5$111
AstraZeneca2$59
Abbott2$35
Lilly USA, LLC2$33
Pfizer1$20
GSK1$18
Merck1$18
AbbVie1$13

How this compares

$307 in reported general payments places this provider in the 70th percentile of 4,983 internal medicine providers in Massachusetts.

See all internal medicine providers in Massachusetts

Medicare billing

Part B allowed, 2024
$224,029
Medicare patients
674
Services billed
6,482

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban125$127,220
OzempicSemaglutide43$38,074
TrulicityDulaglutide34$33,975
XareltoRivaroxaban22$30,237
JardianceEmpagliflozin13$18,671
JanuviaSitagliptin Phosphate17$10,710
FarxigaDapagliflozin Propanediol12$8,988
Rosuvastatin Calcium200$7,276
Combivent RespimatIpratropium/Albuterol Sulfate14$6,915
Metoprolol Succinate326$6,835
Atorvastatin Calcium519$6,800
Breo ElliptaFluticasone/Vilanterol11$6,167
OxycontinOxycodone Hcl13$5,688
BelsomraSuvorexant13$5,463
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,447

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$20$127,220125 claims
Novo NordiskOzempic$111$38,07443 claims
Lilly USA, LLCTrulicity$33$33,97534 claims
MerckJanuvia, Belsomra$18$16,17330 claims
AstraZenecaFarxiga, Symbicort$59$11,69624 claims
GSKBreo Ellipta, Anoro Ellipta$18$11,61423 claims
AbbVieSynthroid$13$2,94156 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 4,983 internal medicine providers in Massachusetts.

Other internal medicine in South Yarmouth

See the full list for Massachusetts

Where these figures come from

Is this you, or does something look wrong? →